---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort P"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort P. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 58 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/bond-003-cohort-p"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort P

<a id="heading-3.1.2"></a>

## 3.1.2 BOND-003 Cohort P

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registry objective for Cohort P

> “To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS”
> “To determine the all-cause High Grade Event Free Survival (HG-EFS) of cretostimogene in up to 75 patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.1-2"></a>

#### Company description of the cohort's purpose

> “We added an additional cohort (BOND-003 Cohort P) of up to 75 patients to evaluate the safety and efficacy of cretostimogene as a monotherapy in the treatment of patients with high-risk BCG-unresponsive NMIBC, Ta or T1 without CIS that have received adequate BCG therapy.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.1-3"></a>

#### Population evaluated as presented at congress

> “BOND-003 Cohort P evaluates cretostimogene in patients with HR BCG-UR with HG Ta/T1 (papillary-only)”
> “Additional bladder-sparing therapies are needed, especially for the BCG-Unresponsive HG Ta/T1 population”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Start of enrollment and site countries

> “First sites opened and patients enrolled March 2024”
> “35+ sites selected across North America and Japan”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.2-2"></a>

#### Cohort initiation date stated in company filings

> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in BCG-unresponsive papillary only NMIBC.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-3.1.2.2-3"></a>

#### Countries enrolling in Cohort P per registry

> “Cohort P(Japan and United States Only) :Open to Enrollment”
> “Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.2-4"></a>

#### Registry dates for the whole BOND-003 study

| Field | Registry entry |
| --- | --- |
| Study start | “Study Start (Actual) 2020-10-27” |
| Primary completion | “Primary Completion (Estimated) 2030-06-16” |
| Study completion | “Study Completion (Estimated) 2031-12-24” |

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.2-5"></a>

#### Enrollment status reported in a 2025 trial-in-progress poster

> “Completed Enrollment”
> “35+ Sites Globally”

Source: [Tyson et al. (2025c)](https://cgoncology.com/wp-content/uploads/2025/11/SIU_TIPs_Bond-003-Cohort-P_Poster_Final-1.pdf)

<a id="topic-3.1.2.2-6"></a>

#### Geographic distribution of enrolled participants

> “96.4% of patients in US”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.2-7"></a>

#### Timing of the next data readout

> “BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Single-arm, open-label design with intravesical administration

> “Single-Arm, Open-Label, IVE Administration”
> “Primary Endpoint: HG Event Free Survival”
> “Mandatory biopsies at 12-month assessment”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.3-2"></a>

#### Registry design details

> “Allocation : Non-Randomized Interventional Model : Single Group Assignment Masking : None (Open Label)”
> “Cohort C and Cohort P will be analyzed and reported separately.”
> “Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.3-3"></a>

#### Response assessment schedule

> “Response assessments include cystoscopy (biopsy as indicated) & cytology every 3 months for first 2 years and every 6 months starting Year 3”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Response assessment schedule as stated in November 2026

> “Response assessments include cystoscopy & cytology every 3 months for first 2 years and every 6 months starting Year 3, biopsy at 12 months”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Regulatory role of the cohort after FDA feedback, November 2026

> “Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027”
> “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-3.1.2.3-6"></a>

#### Phase designation in the November 2026 investor presentation

> “Cohort P is a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.3-7"></a>

#### Phase designation in company filings and releases

> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease.”
> “Topline data from the Phase 3 BOND-003 Cohort P that was presented as a late-breaking abstract at the SUO 26th Annual Meeting in December 2025 showed that cretostimogene, as a single agent in patients with BCG-UR papillary-only NMIBC, demonstrated encouraging High-Grade Event-Free Survival (HG-EFS).”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Cohort P inclusion criteria

> “Have ECOG performance status of 0 to 2.”
> “Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG-unresponsive HG Ta/T1 papillary disease without CIS.”
> “Pathologically confirmed recurrent HG Ta/T1 papillary disease without CIS within 6 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).”
> “Patients with HG Ta: Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG”
> “Patients with HG T1: Patients may be eligible after the initial induction alone (5 of 6 doses of an induction course) as the qualifying BCG treatment.”
> “Completion (last dose) of qualifying BCG treatment within 12 months of study enrollment.”
> “Pathological confirmation of BCG-unresponsive HG Ta/T1 papillary disease without CIS within 14 days of study enrollment.”
> “Have all Ta and/or T1 disease resected, prior to study treatment (e.g., prior to Day 1 treatment).”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria shared by Cohorts C and P

> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer.”
> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of cretostimogene.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.4-3"></a>

#### Definition of BCG-unresponsive papillary disease as presented at congress

> “Enrolled patients with HG Ta/T1 without CIS”
> “BCG-Unresponsive defined as recurrent HG Ta/T1 within 6 months of last adequate BCG dose per FDA guidance”
> “HG T1 after single BCG induction course may be eligible”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Dose, transduction-enhancing agent, and schedule per registry

> “In Cohort P, cretostimogene will be administered at a dose of 1 × 1012vp IVE following instillation of 5% DDM.”
> “Cretostimogene will be administered every week for 6 treatments on Weeks 1, 2, 3, 4, 5, and 6.”
> “If the patient has recurrence at Week 13 or any timepoint, the patient will receive a second induction of 6 weekly treatments (Weeks 13, 14, 15, 16, 17, and 18.).”
> “If the tumor has not returned they will receive 3 weekly treatments every 12 weeks (approximately 3 months) starting Weeks 13, 14, and 15 through Week 51 (approximately 12 months), and then every 6 months starting at Weeks 73, 74, and 75 (approximately 18 months) through Month 36.”
> “Transduction-enhancing agent.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.5-2"></a>

#### Induction, maintenance, and second induction courses

> “Induction Course: Weekly x 6”
> “3-yr Maintenance Course: Weekly x 3 Q3M for Year 1 Weekly x 3 Q6M for Year 2-3”
> “Second Induction: Weekly x 6 for non-responders”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using High-grade Event-free Survival as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint per registry and congress presentations

> “To determine the high-grade EFS of cretostimogene in patients with BCG-unresponsive HG Ta/T1 papillary disease without CIS”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

> “Primary Endpoint HG-EFS”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

> “The study’s primary endpoint is High-Grade Event-Free Survival (HG-EFS).”

Source: [CG Oncology SUO 2025 data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/new-cretostimogene-grenadenorepvec-data-highlight-its-potential)

<a id="topic-3.1.2.6.1-2"></a>

##### Primary endpoint per the Form 10-K description of the cohort

> “The primary endpoint of this cohort is overall event-free survival, with secondary endpoints including safety, high-grade recurrence-free survival (RFS), low-grade RFS, PFS, cystectomy-free survival, and bladder cancer specific survival.”
> “The study’s primary endpoint is HG-EFS, and as of the September 1, 2025 data cut-off, in 51 efficacy evaluable patients, Kaplan-Meier estimates of HG-EFS at 3- 6- and 9-months are 95.7% (95% CI 83.8 – 98.9), 84.6% (95% CI 68.6 – 92.9%) and 80.4% (95% CI 62.3-90.4%), respectively.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.6.1-3"></a>

##### Definition of high-grade event-free survival used in the analysis

> “HG-EFS time from first study treatment (first re-induction dose) to high-grade recurrence, progression, death, or censoring.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### FDA recommendation for resected papillary disease

> “For patients without active disease (disease was resected at or before trial entry), FDA recommends a randomized, controlled trial design using a time-to-event endpoint such as recurrence-free survival.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.2.6.1-5"></a>

##### Sponsor's summary of FDA guidance on endpoints

> “Single-arm trials appropriate for BCG-UR NMIBC studies”
> “Time-to-event endpoint for patients with completely resected Ta/T1 disease”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="topic-3.1.2.6.1-6"></a>

##### International Bladder Cancer Group recommendations for papillary disease

> “Primary end points should include time to recurrence or recurrence-free survival (RFS) for fully resected papillary disease (because these patients have no evidence of disease at study entry)”
> “For patients with papillary disease that is BCG unresponsive, we consider recurrence-free rates of 30% at 12 months and 25% at 18 months as clinically meaningful.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

> “In scenarios where patients with CIS (with or without papillary disease) and papillary-only disease are evaluated separately, CR rate at 6 months and RFS, respectively, are appropriate primary end points.”
> “RFS in this setting includes death as an event and not a competing risk, distinct from low- and intermediate-risk NMIBC.”

Source: [Kamat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10713193/)

<a id="topic-3.1.2.6.1-7"></a>

##### Benchmarks cited by the sponsor for BCG-unresponsive papillary disease

> “Benchmarks reported from recent meta-analysis for BCG-UR HG Ta/T1 NMIBC”
> “73% at 3 mo”
> “58% at 6 mo”
> “48% at 12 mo”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.6.1-8"></a>

##### Secondary endpoints per registry

> “Cohort C and Cohort P: Assess high-grade reoccurrence free survival (RFS)”
> “Cohort C and Cohort P: Assess progression free survival (PFS )”
> “Cohort C and Cohort P : Cystectomy free survival”
> “Cohort C and Cohort P: Evaluate the safety of Cretostimogene”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.6.1-9"></a>

##### Secondary and additional endpoints per congress presentations

> “Secondary Endpoints RFS, PFS, CFS, CSS”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

> “HG RFS, LG RFS”
> “Bladder cancer-specific survival”
> “All-cause EFS”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment

> “Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer.”
> “Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75.”
> “Enrollment (Estimated) 190”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants treated and evaluable at the September 2025 data cutoff

> “Cohort P (N=56):”
> “Patients in Safety Dataset N=56”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

> “At median follow-up 6 months, 51 patients are efficacy evaluable”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Efficacy population stated in the November 2026 investor presentation

| Field | Cretostimogene, BOND-003 Cohort P |
| --- | --- |
| Efficacy population | “N=54” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants in the initial analysis, April 2025

> “Data from first 24 treated patients”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Safety and efficacy-evaluable analysis sets

> “Patients in Safety Dataset”
> “At median follow-up 6 months, 51 patients are efficacy evaluable”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.2-2"></a>

##### Kaplan-Meier estimation and censoring

> “Kaplan-Meier Estimate for High Grade Event-Free Survival”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”
> “Time from first treatment or re-induction (Months)”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Separate analysis of the two cohorts

> “Cohort C and Cohort P will be analyzed and reported separately.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Follow-up, re-induction, cystectomy, and treatment completion

> “Median follow-up: 6.0 months”
> “8 patients were re-induced at 3 months”
> “No patients underwent RC”
> “No treatment related discontinuations”
> “98.2% received all protocol defined treatments”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.1-2"></a>

##### Number re-induced as stated in November 2026

> “11 patients received re-induction”
> “98.2% of patients received protocol defined treatments”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographics and disease characteristics of the safety dataset

| Characteristic | n | % |
| --- | --- | --- |
| Male | “44” | “78.6” |
| Female | “12” | “21.4” |
| Age, mean (SD), years | “71.6 (9.3)” | |
| Age, median (range), years | “74.0 (45-87)” | |
| Age < 65 years | “13” | “23.2” |
| Age ≥ 65 and < 75 years | “18” | “32.1” |
| Age ≥ 75 years | “25” | “44.6” |
| ECOG PS 0 | “48” | “85.7” |
| ECOG PS 1 | “8” | “14.3” |
| HG Ta at study entry | “33” | “58.9” |
| HG T1 at study entry | “23” | “41.1” |
| Prior BCG instillations, median (range) | “9.0 (5 – 21)” | |

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### Race and enrollment by country

> “White (87.5%)”
> “96.4% of patients in US”
> “High-Risk population enrolled, with 41.1% HG T1 at baseline”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.2-3"></a>

##### Tumor stage at study entry as stated in November 2026

| Characteristic | n | % |
| --- | --- | --- |
| HG Ta at study entry | “37” | “66.1” |
| HG T1 at study entry | “19” | “33.9” |

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### High-grade event-free survival at the September 2025 data cutoff

> “95.7% Est. 3-mo HG-EFS [95% CI: 83.8, 98.9]”
> “84.6% Est. 6-mo HG-EFS [95% CI: 68.6, 92.9]”
> “80.4% Est. 9-mo HG-EFS [95% CI: 62.3, 90.4]”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-2"></a>

##### Same estimates labeled as high-grade recurrence-free survival on the SUO 2025 slide

> “95.7% Est. 3-mo HG-RFS [95% CI: 83.8, 98.9]”
> “84.6% Est. 6-mo HG-RFS [95% CI: 68.6, 92.9]”
> “80.4% Est. 9-mo HG-RFS [95% CI: 62.3, 90.4]”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.3-3"></a>

##### High-grade event-free survival by tumor stage

| Time point | HG Ta | HG T1 |
| --- | --- | --- |
| 3 months | “92.8% (3 mo)” | “100% (3 mo)” |
| 6 months | “75.9% (6 mo)” | “100% (6 mo)” |
| 9 months | “75.9% (9 mo)” | “87.5% (9 mo)” |

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-4"></a>

##### Progression, cystectomy, and metastatic disease

> “No patients underwent RC”
> “No progression to MIBC”
> “1 pt progressed to metastatic urothelial carcinoma despite clinical complete response in the bladder.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.8.3-5"></a>

##### Company report of the topline results

> “As of the September 1, 2025, data cut-off, in 51 efficacy evaluable patients, Kaplan-Meier estimates of HG-EFS at 3- 6- and 9-months are 95.7% (95% CI 83.8 – 98.9), 84.6% (95% CI 68.6 – 92.9%) and 80.4% (95% CI 62.3-90.4%), respectively.”

Source: [CG Oncology SUO 2025 data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/new-cretostimogene-grenadenorepvec-data-highlight-its-potential)

<a id="topic-3.1.2.8.3-6"></a>

##### Twelve-month and 24-month estimates as of November 2026

| Time point | Cretostimogene, BOND-003 Cohort P |
| --- | --- |
| 3 months | “95.7 [95% CI: 83.8, 98.9]” |
| 6 months | “84.6 [95% CI: 68.6, 92.9]” |
| 9 months | “80.4 [95% CI: 62.3, 90.4]” |
| 12 months | “Not Yet Reached” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.2.8.3-7"></a>

##### Initial results in the first 24 treated participants, April 2025, superseded in December 2025

> “Data from first 24 treated patients”
> “Strong early responses with 90.5% HG-RFS (95% CI: 77.9-100%) at 3 and 9 Months”
> “90.5% Est. 6-mo HG-RFS [95% CI: 77.9, 100.0]”

Source: [Tyson (2025b)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_P_Learning_Lab.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Treatment-related adverse events reported in more than 10% of participants

| Preferred term | Any grade, n (%) | Grade ≥ 3, n (%) |
| --- | --- | --- |
| Participants with ≥1 TRAE | “40 (71.4%)” | “0 (0)” |
| Bladder spasm | “26 (46.4%)” | “0 (0)” |
| Dysuria | “22 (39.3%)” | “0 (0)” |
| Pollakiuria | “14 (25.0%)” | “0 (0)” |
| Urgency | “11 (19.6%)” | “0 (0)” |

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.5-2"></a>

##### Severity, serious events, deaths, and dosing interruptions

> “Safety data cutoff as of 01SEP2025”
> “Most AEs were Grade 1-2”
> “0% Grade ≥ 3 TRAEs, Serious TRAE, deaths”
> “No dose delays, missed doses due to TRAEs”
> “No treatment related discontinuations”

Source: [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf)

<a id="topic-3.1.2.8.5-3"></a>

##### Safety summary in the Form 10-K

> “A favorable safety and tolerability profile was observed as of the September 1, 2025 safety data cutoff, with no Grade 3 or greater TRAEs and no deaths reported.”
> “The most common TRAEs (≥10%) were bladder spasms, dysuria, pollakiuria, and hematuria.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.2.8.5-4"></a>

##### Safety summary as stated in November 2026

> “No grade ≥ 3 TRAEs, serious TRAE, deaths”
> “No dose delays, missed doses, or discontinuations due to TRAEs”

Source: [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: limitations of the Cohort P evidence

- Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
- Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
- Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
- Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
- Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
- Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
- Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
- Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
- Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf); [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [Tyson (2025e)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Topline_Results_from_BOND-003_Cohort_P_Podium.pdf); [Tyson et al. (2025c)](https://cgoncology.com/wp-content/uploads/2025/11/SIU_TIPs_Bond-003-Cohort-P_Poster_Final-1.pdf); [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf); [Bivalacqua et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/11/SIU_2026_BOND-003_Cohort_P_Poster.pdf); [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and); [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-3.1.2.9-2"></a>

#### Interim data maturity and censoring

> “Median follow-up: 6.0 months”
> “01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.”

Source: [Clinton et al. (2026b)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortP-Topline_Poster.pdf)

<a id="topic-3.1.2.9-3"></a>

#### Single-arm design and interpretability of time-to-event endpoints

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.2.9-4"></a>

#### Cross-trial comparisons in sponsor materials

> “Note: These data are not based on head-to-head or comparator studies.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
